

LISTED OSE: AZT | Swiss Nordic Bio 2026

The Compounding Enzyme Platform

High-margin enzymes embedded in the workflows behind advanced therapies and molecular diagnostics - consumed batch after batch. Profitable and compounding: FY 2025 revenue NOK 118m, H1 2026 sales +27%.

Michael B. Akoh, Chief Executive Officer

Børge Sørvoll, Chief Financial Officer

A unique, scalable and profitable enzyme platform

Who we are

30+ *Years experience*

Enzyme innovator with industry knowledge built over several decades selling direct globally

55 *Full-time employees*

With deep expertise in developing, manufacturing and commercializing high-performance enzymes

118 *MNOK revenue (2025)*

Scalable platform model with positive EBITDA and strong growth drivers

Strengthening market position - more customers seeing the value of our high-performance enzymes
Direct sales to 360+ unique customers



We make viral vectors affordable — and pathogens findable

Cost limits cell & gene therapy. Time limits diagnostics. Both come down to unwanted DNA.

THE REVOLUTION Advanced therapies and molecular diagnostics are scaling fast — and both stall at the same step.

THE CHALLENGE

Advanced therapies

Cell, gene & RNA bioprocessing

- Manufacturing cost limits cell & gene therapy
- Unwanted DNA must be cleared from every batch

Molecular diagnostics

PCR, NGS & metagenomics

- Metagenomic pathogen ID takes days
- The patient's own DNA swamps the signal

HOW ARCTICZYMES SOLVES IT

- Viral vectors become affordable to manufacture
- >40% lower enzyme cost per dose

- We strip out the human DNA — the pathogen shows up
- Days to under 7 hours, sample-to-report

WHERE WE FIT: ~\$28B across two markets, growing 5–17%.

Designed in once in 2020 — FDA PMA decision in 2026


One customer, one enzyme, one test — and a decade of compounding revenue

TIMELINE — DESIGNED IN, THEN LOCKED IN

2020	Designed in	Proteinase selected for a population-scale screening assay
2021	Validated	Customer confirms enzyme performance in their workflow
2022–24	Pivotal trial	Multi-year pivotal trial; AZT supplies throughout
2024	Audit passed	Customer site audit of AZT — no major deviations
2025	Submission	Trial results filed with the FDA
2026	FDA PMA	Approval unlocks the population-screening ramp

ENZYME REVENUE FROM THIS ONE CUSTOMER (MNOK)

History → forecast through commercial launch (illustrative)




READ-ACROSS This is ONE customer and ONE enzyme — and the designed-in pattern that independent research now underwrites.

We sell “picks and shovels” — paid per batch, whoever wins

Annual nuclease revenue per cell & gene therapy account — it scales with batch size and batch count, not with our headcount

CUSTOMER VALUE LADDER — ANNUAL NUCLEASE REVENUE

Per account, per year (kUSD) — clinical stages, then commercial by manufacturing scale



PORTFOLIO MATH

What the pipeline can capture (illustrative estimates)

- 20** Small-scale commercial programs (50L)
≈ **USD 1.5M / yr**
ocular / niche; ~\$75K each, mid case
- 5** Mid-scale commercial programs (500L)
≈ **USD 4M / yr**
niche systemic; ~\$750K each at 500L
- 1** Larger scale commercial programs (2000L)
USD 2–5M / yr
2000L × 37 batches, after value share

PORTFOLIO LOGIC A handful of late-stage programs converting to commercial can re-rate company revenue — off a cost base that barely moves.

Self-funded growth — and a listed share you can own today

Team · IP · what we are looking for · why to own the share

1

Team and track record

55 specialists in enzyme R&D, GMP manufacturing and commercial — selling direct, globally. Momentum: H1 2026 sales +27%, EBITDA NOK 9m

2

IP and know-how

First novel RNA restriction enzyme patent granted April 2026, plus proprietary production and process know-how

3

What we are looking for

Long-term shareholders on the register

4

How you make money

OSE: AZT, liquid and no dilution. Revenue from 120 → 200 MNOK lifts EBITDA margin from ~12% to ~32%

THE EQUATION High gross margin + enzyme consumed with every batch and every test + a fixed cost base = compounding earnings — already visible: H1 2026 sales +27%, EBITDA NOK 9m vs NOK 0.1m

QUESTIONS

Thank you

The compounding enzyme platform — listed on Oslo Børs as AZT.

Michael B. Akoh — Chief Executive Officer

michael.akoh@arcticzymes.com

Børge Sørvoll — Chief Financial Officer

borge.sorvoll@arcticzymes.com

ArcticZymes Technologies ASA | OSE: AZT | www.arcticzymes.com